Absci reports business updates and first quarter 2025 financial and operating results

Initiated dosing of participants in the first-in-human study of abs-101 (anti-tl1a antibody), with interim data expected in the second half of 2025 abs-201 (anti-prlr) non-human primate (nhp) data demonstrate extended half life and high subcutaneous bioavailability; anticipate phase 1 initiation in early 2026 cash, cash equivalents, and short-term investments sufficient to fund operations into the first half of 2027 vancouver, wash. and new york, may 13, 2025 (globe newswire) -- absci corporation (nasdaq: absi), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative design, today reported financial and operating results for the quarter ended march 31, 2025.
ABSI Ratings Summary
ABSI Quant Ranking